Analysts Are Bullish on These Healthcare Stocks: Exact Sciences (EXAS), Neurocrine (NBIX)
Exact Sciences Is Maintained at Buy by B of A Securities
Exact Sciences Analyst Ratings
BofA Securities Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $72
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $86
Exact Sciences (EXAS) Gets a Buy From TD Cowen
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $67 to $86
What 19 Analyst Ratings Have To Say About Exact Sciences
Exact Sciences Is Maintained at Buy by TD Cowen
TD Cowen Maintains Buy on Exact Sciences, Raises Price Target to $86
Exact Sciences Is Maintained at Buy by BTIG
Exact Sciences Analyst Ratings
BTIG Raises Price Target on Exact Sciences to $75 From $65, Maintains Buy Rating
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $67 to $86
Piper Sandler Releases a Buy Rating on Exact Sciences (EXAS)
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $85
Exact Sciences (EXAS) Receives a Buy From Jefferies
Exact Sciences Analyst Ratings
Piper Sandler Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Scotiabank Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70